Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Alfacalcidol Effects on Dendritic Cells in Graves' Disease
NCT02993302Phase 2Completed
- Sponsor
- Dr. Cipto Mangunkusumo Hospital
- Start
- Jul 2014
- Primary completion
- Mar 2015
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of alfacalcidol in Graves' disease (2 arms), sponsored by Dr. Cipto Mangunkusumo Hospital. Primary endpoints: CD80 Level at 1 year, CD206 Level at 1 year and 2 more. Started Jul 2014; status: completed.
02
Drugs
alfacalcidol
03
Conditions
Graves' disease
Beyond the preview
Go deeper on NCT02993302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02993302.